Autoimmune hypothyroidism and thyroid hormone replacement
Research activity is centered on hypothyroidism in people with ongoing symptoms despite standard levothyroxine treatment, with a focus on thyroid hormone balance and persistent fatigue.
- Levothyroxine monotherapy
- LT4/LT3 combination therapy
- Autoimmune thyroid disease
Clinical interest extends to symptom burden in treated thyroid disease, particularly ongoing tiredness and related quality of life concerns.
Triiodothyronine and combination endocrine therapy
The funded research landscape includes the role of triiodothyronine within thyroid replacement strategies, with attention to how combined T4/T3 therapy relates to residual complaints in thyroid dysfunction.
- Triiodothyronine
- T4/T3 replacement
- Persistent symptoms
This area reflects a therapeutic focus on symptom control in patients whose thyroid hormone therapy leaves unresolved tiredness.
Patient-reported outcomes and quality of life
Another clear area of interest is the measurement of tiredness, persistent complaints, and quality of life in individuals living with chronic thyroid-related symptoms.
- Fatigue assessment
- Quality of life
- Persistent complaints
The clinical emphasis is on symptom experience in everyday life, especially among patients who remain symptomatic under standard replacement treatment.
Genetic variation in thyroid response
The research portfolio also includes interest in genetic factors that may influence response to thyroid therapy, particularly variation in DIO2 and MCT10 in relation to treatment-related symptom improvement.
- DIO2 genetic variation
- MCT10 genetic variation
- Individual treatment response
This supports a focus on biologic differences that may shape outcomes in thyroid hormone replacement.
